Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Genetic Testing and Blood-Based Monitoring Improve Understanding and Tracking of Prostate Cancer

By LabMedica International staff writers
Posted on 02 Jun 2025

Many men with aggressive prostate cancer face high recurrence rates despite undergoing treatment. More...

Now, findings of a new study suggest that specific gene mutations may be key to understanding these outcomes and could pave the way for more personalized therapies.

A Phase 2 clinical trial being conducted at UC Davis Comprehensive Cancer Center (Sacramento, CA, USA) is evaluating the use of niraparib (ZEJULA), a PARP inhibitor, administered before prostate cancer surgery. Researchers aim to determine whether this approach can prevent cancer recurrence, particularly in men whose tumors exhibit DNA repair gene mutations. In this pilot study, 11 men with high-risk prostate cancer and identified gene mutations received 200 mg of niraparib daily for 90 days prior to surgery. The median age of participants was 68 years, with a median prostate-specific antigen (PSA) level at diagnosis of 10.7 ng/mL. Genetic alterations observed included germline mutations in BRCA2, MSH6, and CHEK2, as well as somatic mutations in ATM, SPOP, KMT2C, and KMT2D.

While the treatment did not significantly reduce tumor size before surgery, the study highlighted the potential of genetic testing and blood-based monitoring in understanding and tracking prostate cancer. Notably, circulating tumor DNA (ctDNA) analysis proved effective in monitoring tumor evolution and resistance mechanisms in real time, according to the findings presented at the annual American Society of Clinical Oncology (ASCO) conference. The research team is now continuing to analyze the data to better understand why some cancers resist treatment and how to design future therapies that are more tailored to each individual.

“This study shows how complex prostate cancer can be, especially in men with certain gene mutations,” said Marc Dall’Era, chief of UC Davis Health’s Department of Urologic Surgery and lead researcher. “Although responses were variable, especially in patients with BRCA2 mutations, this study points to ctDNA as a promising tool to identify who might benefit from targeted neoadjuvant therapies.”

Related Links:
UC Davis Comprehensive Cancer Center


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Blood Glucose Test Strip
AutoSense Test
New
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.